BRUKER CORP — Form 8-K
Filed November 4, 2026 · analyzed by the 8-K Agent
8-K
▼ Likely negative
significance 42/100
What the filing says
Bruker reported Q3 2026 revenue of $874.0M (+1.6% YoY), with organic growth of only 0.7%. GAAP operating loss was $(91.0)M due to a $174.5M goodwill impairment charge. Non-GAAP operating margin expanded to 16.3% (from 12.3% YoY), and non-GAAP diluted EPS rose 24.4% to $0.56. For 9M 2026, revenue reached $2,536M (+3.1% YoY); organic revenue declined 0.3%. Goodwill impairments totaled $309.4M year-to-date. The company reconfirmed FY2026 guidance of $3.52–$3.56B revenue (1–2% organic growth) and non-GAAP EPS of $2.10–$2.15.
Why this rating
Large impairments ($309M YTD, ~7% of market cap) signal prior overpayment in M&A. Organic growth stalled (−0.3% 9M). Non-GAAP margin expansion masks core challenge. Material but not existential relative to company size.
See more from November 4, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.